The closing price of Qiagen NV (NYSE: QGEN) was $42.70 for the day, down -0.28% from the previous closing price of $42.82. In other words, the price has decreased by -$0.12 from its previous closing price. On the day, 922372 shares were traded.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Ratios:
Our analysis of QGEN’s different ratios will help us gain a deeper understanding of the company. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 8.94 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 30.52. For the most recent quarter (mrq), Quick Ratio is recorded 1.62 and its Current Ratio is at 1.99. In the meantime, Its Debt-to-Equity ratio is 0.42 whereas as Long-Term Debt/Eq ratio is at 0.26.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Wells Fargo on December 19, 2023, initiated with a Equal Weight rating and assigned the stock a target price of $44.
Goldman Upgraded its Neutral to Buy on December 07, 2023, while the target price for the stock was maintained at $50.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, QGEN now has a Market Capitalization of 9.45B and an Enterprise Value of 9.93B. As of this moment, Qiagen’s Price-to-Earnings (P/E) ratio for their current fiscal year is 27.99, and their Forward P/E ratio for the next fiscal year is 18.55. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 16.86. For the stock, the TTM Price-to-Sale (P/S) ratio is 4.81 while its Price-to-Book (P/B) ratio in mrq is 2.54. Its current Enterprise Value per Revenue stands at 5.05 whereas that against EBITDA is 14.42.
Stock Price History:
Over the past 52 weeks, QGEN has reached a high of $47.69, while it has fallen to a 52-week low of $34.74. The 50-Day Moving Average of the stock is 43.83, while the 200-Day Moving Average is calculated to be 42.85.
Shares Statistics:
QGEN traded an average of 1.24M shares per day over the past three months and 880.97k shares per day over the past ten days. A total of 226.45M shares are outstanding, with a floating share count of 220.34M. Insiders hold about 0.46% of the company’s shares, while institutions hold 59.40% stake in the company. Shares short for QGEN as of Feb 29, 2024 were 3.07M with a Short Ratio of 2.48, compared to 2.49M on Jan 31, 2024. Therefore, it implies a Short% of Shares Outstanding of 1.39% and a Short% of Float of 1.82%.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.00%, it implies a Forward Annual Dividend Yield of 2.94%. The current Payout Ratio is 0.00% for QGEN, which recently paid a dividend on Jan 30, 2024 with an ex-dividend date of Jan 30, 2024. Stock splits for the company last occurred on Jan 25, 2017 when the company split stock in a 962:1000 ratio.
Earnings Estimates
The firm’s stock currently is rated by 13 analysts. On average, analysts expect EPS of $0.44 for the current quarter, with a high estimate of $0.45 and a low estimate of $0.43, while EPS last year was $0.53. The consensus estimate for the next quarter is $0.52, with high estimates of $0.54 and low estimates of $0.51.
Analysts are recommending an EPS of between $2.23 and $2.02 for the fiscal current year, implying an average EPS of $2.11. EPS for the following year is $2.3, with 22 analysts recommending between $2.48 and $2.21.
Revenue Estimates
It is expected that $90B in revenue will be generated in the current quarter, according to 12 analysts. It ranges from a high estimate of $460.1M to a low estimate of $452.4M. As of the current estimate, Qiagen NV’s year-ago sales were $480.54M, an estimated decrease of -4.90% from the year-ago figure. For the next quarter, 12 analysts are estimating revenue of $499.92M, an increase of 1.50% over than the figure of -$4.90% in the same quarter last year. There is a high estimate of $507M for the next quarter, whereas the lowest estimate is $491.5M.
A total of 23 analysts have provided revenue estimates for QGEN’s current fiscal year. The highest revenue estimate was $2.07B, while the lowest revenue estimate was $2B, resulting in an average revenue estimate of $2.01B. In the same quarter a year ago, actual revenue was $1.97B, up 2.30% from the average estimate. Based on 23 analysts’ estimates, the company’s revenue will be $2.14B in the next fiscal year. The high estimate is $2.22B and the low estimate is $2.11B. The average revenue growth estimate for next year is up 6.70% from the average revenue estimate for this year.
